Fluocinolone Acetonide

Spécifications

67-73-2Numéro CAS

200-668-5Numéro CE

(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-oneNom IUPAC

C24H30F2O6Formule chimique

452.5 g/molMasse molaire

FLUOCINOLONE ACETONIDE; 67-73-2; Synalar; Fluonid; Flucinar; Flupollon; Synamol; Synandone; Jellin; Coriphate; Dermalar; Fluovitif; Percutina; Radiocin; Retisert; Synandrone; Tefunote; Localyn; Sinalar; Synotic; Synsac; Fluocet; Fluotrex; Derma-smoothe/fs; Synalar-HP; Localyn Syntex; Cortiplastol; Prodermin; Iluvien; Capex; Fs Shampoo; Fluocinolone 16,17-acetonide; Fluocinolonacetonidum; Acetonide de fluocinolone; 6alpha-Fluorotriamcinolone acetonide; Fluocinoloni acetonidum; RS-1401 AT; Oto-synalar; NSC-92339; DTXSID0040674; Flucinolone acetonide; Fluocinolide (acetate); Dermotic; 6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide; acetonido de fluocinolona; 0CD5FD6S2M; YUTIQ; NSC92339; (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; DTXCID8020674; CHEBI:31623; OTOVEL COMPONENT FLUOCINOLONE ACETONIDE; ILUVIEN COMPONENT FLUOCINOLONE ACETONIDE; Fluortriamcinolone Acetonide; Jellisoft; Co Fluocin; Synalar HP; Derma Smooth FS; (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one; Acetonide, Fluocinolone; Acetonide, Fluortriamcinolone; Synalar fte; Synalar-n; Flac Otic Oil; (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo(10.8.0.0^(2,9).0^(4,8).0^(13,18))icosa-14,17-dien-16-one; (6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione; FLAC; NOXIPAK; XILAPAK; fluocinolone (alcohol); RefChem:55208; Synalar Cream Veterinary; Synalar Solution Veterinary; FLUOCINONIDE ACETONIDE; Fluocinolone Acetonide Topical; Fluocinolone Acetonide 0.01%; C05AA10; D07AC04; S01BA15; S02BA08; FLUOCINOLONE ACETONIDE and UREA; Fluocinolone Acetonide Topical Solution USP, 0.01%; 200-668-5; 6alpha,9-Difluoro-11beta,21-dihydroxy-16alpha,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione; Synemol; component of Neo-Synalar; Fluocinolone (Acetonide); Dermatin (steroid); MFCD00010525; Fluocinolone acetonide (Flucort-N); MLS000028545; MLS001076276; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; (6alpha,9alpha,11beta,16beta)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; SMR000058329; Fluocinolone acetonide [DCIT]; (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one; Fluocinoloni acetonidum [INN-Latin]; Acetonida de fluocinolona; RS 1401AT; 6.alpha.-Fluorotriamcinolone acetonide; CAS-67-73-2; Retisert (TN); Fluocet (TN); Synalar (TN); Acetonide de fluocinolone [INN-French]; Acetonida de fluocinolona [INN-Spanish]; CCRIS 3250; HSDB 3083; 6.Alpha.,9-Difluoro; EINECS 200-668-5; NSC 92339; UNII-0CD5FD6S2M; Flucort-N; Fluzon [Steroid]; NCGC00021301-04; 6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide; 6a,9-Difluoro-11ss,21-dihydroxy-16a,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione; fluocinolone-acetonide; Fluocinolone acetonide intravitreal implant; 6.alpha.,17-acetonide; Opera_ID_1295; F0657; Fluocinolone acetonide [USAN:USP:INN:JAN]; Fluocinolone acetonide CRS; CHEMBL989; SCHEMBL4795; Fluocinolone acetonide - BP; 6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide; GTPL7077; orb1310684; orb3025531; 6?-Fluorotriamcinolone acetonide; HY-B0415R; MSK2245; HMS2090I14; HMS2230D13; HMS3259G12; HMS3715J11; FLUOCINOLONE ACETONIDE [MI]; (2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-Difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one; HY-B0415; Fluocinolone (Acetonide) (Standard); FLUOCINOLONE ACETONIDE [INN]; FLUOCINOLONE ACETONIDE [JAN]; Tox21_110869; Tox21_302364; AC-429; AC1069; EBC-27131; FLUOCINOLONE ACETONIDE [HSDB]; FLUOCINOLONE ACETONIDE [USAN]; MSK2245-100A; s2470; FLUOCINOLONE ACETONIDE [VANDF]; AKOS015963144; FLUOCINOLONE ACETONIDE [MART.]; MSK2245-1000A; Tox21_110869_1; CCG-221165; DB00591; FF15770; FLUOCINOLONE ACETONIDE [USP-RS]; FLUOCINOLONE ACETONIDE [WHO-DD]; NC00562; Fluocinolone acetonide (JP18/USP/INN); NCGC00021301-06; NCGC00021301-12; NCGC00255654-01; 4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; AS-13690; BF176452; NCI60_042042; SY057543; Fluocinolone Acetonide (anti-inflammatory); FLUOCINOLONE ACETONIDE [GREEN BOOK]; Fluocinolone acetonide, analytical standard; FLUOCINOLONE ACETONIDE [ORANGE BOOK]; F4582; FLUOCINOLONE ACETONIDE [EP MONOGRAPH]; FLUOCINOLONE ACETONIDE [USP IMPURITY]; NS00008944; T0367; FLUOCINOLONE ACETONIDE [USP MONOGRAPH]; D01825; AB00383017-10; AB00383017_11; EN300-7410632; Fluocinolone acetonide for system suitability CRS; TRI-LUMA COMPONENT FLUOCINOLONE ACETONIDE; F978955; NEO-SYNALAR COMPONENT FLUOCINOLONE ACETONIDE; Q924467; SR-01000000109; SR-01000000109-2; BRD-K94353609-001-21-6; difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one; Fluocinolone acetonide Solution in Acetonitrile, 1000ug/mL; Fluocinolone acetonide Solution in Acetonitrile, 100ug/mL; 6.alpha., 9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide; Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard; Fluocinolone acetonide, United States Pharmacopeia (USP) Reference Standard; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacé Fluocinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard; Fluocinolone Acetonide, Pharmaceutical Secondary Standard; Certified Reference Material; WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF; (2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H); (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (6|_,11|_,16|_)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; (6|A,11|A,16|A)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione; 6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone; Fluocinolone acetonide for peak identification, European Pharmacopoeia (EP) Reference Standard; Pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-Synonymes